Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) has named Alex Howarth its new chief operating officer. He was most recently president at Lycera. His experience also includes positions at moksha8, Vitae Pharmaceuticals, and GlaxoSmithKline (NYSE: [[ticker:GSK]]). Howarth joins Boston-based Akcea following a corporate shakeup in September that led to the departure of three executives. The rare disease drug developer has two drugs on the market, inotersen (Tegsedi) and volanesorsen (Waylivra).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
